Neuroprotective effect of engineered Clostridium butyricum‐pMTL007‐GLP ‐1 on Parkinson's disease mice models via promoting mitophagy
Bioengineering & Translational Medicine · 2023-05 · 8 (3)
DOI: 10.1002/btm2.10505 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 17.03.2023. Verfasst von Yun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology The First Affiliated Hospital of Nanchang University Nanchang Jiangxi Province P. R. China 330006. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Parkinson's disease (PD) is a common neurodegenerative disease with limited treatment and no cure, hence, broadening PD drug spectrum is of great significance. At present, engineered microorganisms are attracting increasing attention. In this study, we constructed an engineered strain of Clostridium butyricum ‐GLP‐1, a C. butyricum (a probiotic) that consistently expresses glucagon‐like peptide‐1 (GLP‐1, a peptide‐based hormone with neurological advantage) in anticipation of its use in PD treatment. We further investigated the neuroprotective mechanism of C. butyricum ‐GLP‐1 on PD mice models induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. The results indicated that C. butyricum ‐GLP‐1 could improve motor dysfunction and ameliorate neuropathological changes by increasing TH expression and reducing the expression of α‐syn. Moreover, we confirmed that C. butyricum ‐GLP‐1 improved microbiome imbalance of PD mice by decreasing the relative abundance of Bifidobacterium at the genus level, improved gut integrity, and upregulated the levels of GPR41/43. Surprisingly, we found it could exert its neuroprotective effects via promoting PINK1/Parkin mediated mitophagy and attenuating oxidative stress. Together, our work showed that C. butyricum ‐GLP‐1 improves PD by promoting mitophagy, which provides an alternative therapeutic modality for PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology The First Affiliated Hospital of Nanchang University Nanchang Jiangxi Province P. R. China 330006.
- Institute of Translational Medicine Nanchang University Nanchang Jiangxi Province P. R. China 330031.
ORCID-Profile: Wen-Jie Chen, Ting-Tao Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Chen, W. J., Han, Y. Y., Xu, X., Yang, A. X., Wei, J., Hong, D. J., Fang, X., & Chen, T. T. (2023). Neuroprotective effect of engineered Clostridium butyricum‐pMTL007‐GLP ‐1 on Parkinson's disease mice models via promoting mitophagy. Bioengineering & Translational Medicine, 8(3). https://doi.org/10.1002/btm2.10505
Vancouver
Wang Y, Chen WJ, Han YY, Xu X, Yang AX, Wei J, et al. Neuroprotective effect of engineered Clostridium butyricum‐pMTL007‐GLP ‐1 on Parkinson's disease mice models via promoting mitophagy. Bioengineering & Translational Medicine. 2023;8(3). doi:10.1002/btm2.10505
BibTeX
@article{Wang2023,
author = {Wang, Yun and Chen, Wen-Jie and Han, Yi-Yang and Xu, Xuan and Yang, Ai-Xia and Wei, Jing and Hong, Dao-Jun and Fang, Xin and Chen, Ting-Tao},
title = {Neuroprotective effect of engineered Clostridium butyricum‐pMTL007‐GLP ‐1 on Parkinson's disease mice models via promoting mitophagy},
journal = {Bioengineering & Translational Medicine},
year = {2023},
volume = {8},
number = {3},
doi = {10.1002/btm2.10505}
}
EUVIMED